Btg Share Discussion Threads

[fhmktg] 27/9/2018 08:33

The replacement policy for Crofab is defensive, of course, but taken together with the other moves place pressure on Anavip to match them, increasing their costs of entry into the market.Confidence in efficacy is proven for Crofab and they are extending their range of indications.All good moves for a market leader to defend their position.Real price moves might come later, but not until Anavip actually starts to impact on stock ordering.The actual launch and pricing policy for Anavip are still not announced as far as I know.The next 12-18 months will be 'interesting'Much more important this year is the ongoing policy for Varithena.........

[bargainbob] 27/9/2018 07:30

I see the phantom downticker was busy last night.

[cockneytrader] 26/9/2018 14:32

From the most recent RNS looks that they are taking Anavip competition very seriously!

[cockneytrader] 26/9/2018 11:31

Results due on 13th Nov, so it should be next week. If I were a betting man, I would say Thursday next week.

[gregsc] 26/9/2018 11:09

CT. How do you know the statement will be next week.
BTG just say sometime in October, although last year it was on the 6th.

[cockneytrader] 26/9/2018 10:01

The statement next week will be interesting. It should update us on Pneumerx and Varithena. I am bearish on both products for obvious reason.

The results from the rest of the group should at least be in line with expectations, and I have no reason to believe otherwise.

[gregsc] 25/9/2018 09:25

I agree. This is my biggest investment, although I am showing a large profit at the moment, it is still disappointing. Should have sold earlier this year.
Talked to Louise a while ago at the AGM but she wasn't very forthcoming.

[bargainbob] 23/9/2018 08:46

Alord will miss you , please keep visiting the thread from time to time .

[a1ord53] 21/9/2018 10:14

Sold , glad that market pushed dead cat up .Varithena will be wrote off , Crofab will decrease sales, bead business loosing money . Thanks algo men , who pushed share price up.

[cannyshoveyergrannyoffthebus] 20/9/2018 12:22

have we missed somethinng ?

[fhmktg] 20/9/2018 12:02

Come. On guys!Say something nice- this is a good innovative development in one of the most exciting treatment areas for tumours...especially prostate.You never know you might be in line to benefit!

[fhmktg] 20/9/2018 08:08

Well done team!Innovate, develop, launch, grow!

[bargainbob] 14/9/2018 16:14

Agree , time for Louise to step aside.

[a1ord53] 14/9/2018 15:00

Next week 6£ or 5£ ???
News flow until now very weak
Dame is anochronisme imo
New management is hope

[a1ord53] 13/9/2018 18:23

BTG reaches settlement regarding CroFab® patent litigation

10 October 2014
London, UK, 10 October 2014: BTG plc (LSE: BTG) today announces that it has settled its United States patent infringement complaint against Instituto Bioclon (Bioclon) of Mexico and Rare Disease Therapeutics, Inc. (RDT) of Nashville, Tennessee. The case was filed by BTG with the International Trade Commission in October 2013 based upon the unlawful and unauthorised importation and sale into the US of certain crotalid antivenom pharmaceutical compositions that infringe one or more claims of BTG’s US Patent No. 8,048,414 (“the ‘414 patent”).

Under the terms of the agreement, BTG would allow Bioclon to begin selling crotalid antivenom relying on BTG’s 414 patent from October 2018, subject to Bioclon receiving regulatory approval for its antivenom product. BTG will receive a single-digit royalty on sales of any Bioclon product relying on the 414 patent until the end of the exclusivity period in 2028. In addition, Bioclon will withdraw its legal challenge to the validity of the 414 patent. BTG has agreed to reimburse Bioclon USD $6 million for its legal fees and costs incurred.

Louise Makin, Chief Executive Officer at BTG, said: “Settling this litigation is good for our business as it removes uncertainty for our investors and other stakeholders. Most importantly, it allows us to concentrate on what we do best, delivering a first-class treatment and supporting our customers and their patients by continuing to invest in a product that has treated over 40,000 people.”

[dp1umb] 13/9/2018 18:05

Also Alord there are some stunning predictions for the sales growth of Zytiga ( although I don’t think anyone knows how the expiring patents will effect BTGs royalties??

[dp1umb] 13/9/2018 17:48

Haven’t BTG an agreement with a conflicting patient with the manufacturer of ANAVIP ??

[a1ord53] 13/9/2018 15:49

Dp1umb - just read release. Its 24 months increase from current 36 months, but only for new manufactured products without mercury... All existing vaccines should be replaced. This is some saving , but if Anavip will come , which is few times cheaper, for Crofab will be not easy to compete. Btg should buy Anavip imo.

[dp1umb] 13/9/2018 14:43

Alord you haven’t had time to post the positive on Crofab announced today regarding shelf life?

[a1ord53] 13/9/2018 09:58

Fhmktg , I did go to Varithena.com and been transfered to Btg site with icon ‘Find a doctor’.
hxxps://www.btg-im.com/en-US/Varithena/Home

I did put zip codes of California, New York, Florida and got just 7 doctors for all these states(- not a lot ?), who are offering Varithena treatment and I called 3 of them in New York state area and asked if Varisolve is good or they have better treatments. And they offered me better than Varithena in their opinion treatments. I asked if Vatithena popular by patients and answer was that some patients do , but other treatments cheaper and more popular.So not clear annswer, but for some reason not great apreciation of Varithena according what I heard.
Also crofab will probably get competition in October from I gues Anavip, which much cheaper and has FDA aproval .
I closed 70 % of my remaining holding at average price 572p and if it drops back tp low fiviesh , will buy again.